Extraction and Identification of Antibacterial Secondary Metabolites from Marine Streptomyces Sp. VITBRK2

Overview

Journal Int J Mol Cell Med

Specialty Genetics

Date 2014 Oct 16

PMID 25317399

Citations 26

Authors

Benita Mercy Rajan

Krishnan Kannabiran

Affiliations

Soon will be listed here.

Abstract

Actinomycetes were isolated from marine sediment samples collected from the east coast of Chennai, Tamil Nadu, India. Well diffusion and agar plug methods were used for the evaluation of antibiotic production by these isolates against drug resistant Methicillin- resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococci (VRE). The potential isolate VITBRK2 was mass cultured for morphological and physiological characterization. The culturing conditions of the isolate were optimized and the recommendations of International Streptomyces Project were followed for the assimilation of carbon and nitrogen sources. The isolate was identified by comparing the properties with representative species in the key of Nonomura and Bergey's Manual of Determinative Bacteriology. Ethyl acetate extract prepared from the cell free culture broth of the isolate was analyzed using HPLC- diode array technique to characterize the metabolites and identify the antibiotics. VITBRK2 was found to be Gram-positive rod grey color aerial mycelium production. It was also non motile in nature with spiral spore chain morphology. VITBRK2 was identified as Streptomyces and designated as Streptomyces sp. VITBRK2. HPLC-DAD analysis showed the presence of indolo compounds (3- methyl-indole and 2-methyl- indole) along with amicoumacin antibiotic. The observed activity of Streptomyces sp. VITBRK2 against MRSA and VRE strains may be due to the presence of indolo compounds in the isolate. The results of this study suggested that secondary metabolites produced by Streptomyces sp. VITBRK2 could be used as a lead to control drug resistant bacterial pathogens.

Citing Articles

Evaluation of the Cytotoxicity of Secondary Bioactive Compounds Produced by in Soil against a Colon Cancer Cell Line.

Hosseini M, Sepahi A, Amini K, Torbati M, Mousavi M Int J Mol Cell Med. 2024; 13(1):105-119.

PMID: 39156873 PMC: 11329933. DOI: 10.22088/IJMCM.BUMS.13.1.105.

Probiotic potential of Streptomyces levis strain HFM-2 isolated from human gut and its antibiofilm properties against pathogenic bacteria.

Verma J, Devi S, Narang A, Kaur S, Manhas R BMC Microbiol. 2024; 24(1):208.

PMID: 38862894 PMC: 11165917. DOI: 10.1186/s12866-024-03353-x.

Metabolic Comparison and Molecular Networking of Antimicrobials in Species.

Thapa B, Huo C, Budhathoki R, Chaudhary P, Joshi S, Poudel P Int J Mol Sci. 2024; 25(8).

PMID: 38673777 PMC: 11050201. DOI: 10.3390/ijms25084193.

Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from via an Epicutaneous Infection Model.

Karayildirim C, Sahiner A, Caliskan S, Soylu F, Gokhan A, Eroglu E ACS Omega. 2024; 9(7):8397-8404.

PMID: 38405438 PMC: 10882681. DOI: 10.1021/acsomega.3c09522.

Acetaminophen-traces bioremediation with novel phenotypically and genotypically characterized 2 Streptomyces strains using chemo-informatics, in vivo, and in vitro experiments for cytotoxicity and biological activity.

Embarez D, Razek A, Basalious E, Mahmoud M, Hamdy N J Genet Eng Biotechnol. 2023; 21(1):171.

PMID: 38112983 PMC: 10730784. DOI: 10.1186/s43141-023-00602-w.

References

Enright M . The evolution of a resistant pathogen--the case of MRSA. Curr Opin Pharmacol. 2003; 3(5):474-9. DOI: 10.1016/s1471-4892(03)00109-7. View

PRAUSER H . APTNESS AND APPLICATION OF COLOUR CODES FOR EXACT DESCRIPTION OF COLOURS OF STREPTOMYCETES. Z Allg Mikrobiol. 1964; 4:95-8. View

Levy S, Marshall B . Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004; 10(12 Suppl):S122-9. DOI: 10.1038/nm1145. View

Yang X, Zhang G, Ying J, Yang B, Zhou X, Steinmetz A . Isolation, characterization, and bioactivity evaluation of 3-((6-methylpyrazin-2-yl)methyl)-1H-indole, a new alkaloid from a deep-sea-derived actinomycete Serinicoccus profundi sp. nov. Mar Drugs. 2012; 11(1):33-9. PMC: 3564155. DOI: 10.3390/md11010033. View

de Lima Procopio R, Silva I, Martins M, de Azevedo J, Magali de Araujo J . Antibiotics produced by Streptomyces. Braz J Infect Dis. 2012; 16(5):466-71. DOI: 10.1016/j.bjid.2012.08.014. View

Chambers H, DeLeo F . Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009; 7(9):629-41. PMC: 2871281. DOI: 10.1038/nrmicro2200. View

Gould I . The epidemiology of antibiotic resistance. Int J Antimicrob Agents. 2008; 32 Suppl 1:S2-9. DOI: 10.1016/j.ijantimicag.2008.06.016. View

Lama A, Pane-Farre J, Chon T, Wiersma A, Sit C, Vederas J . Response of methicillin-resistant Staphylococcus aureus to amicoumacin A. PLoS One. 2012; 7(3):e34037. PMC: 3316591. DOI: 10.1371/journal.pone.0034037. View

Shridhar D, Mahajan G, Kamat V, Naik C, Parab R, Thakur N . Antibacterial activity of 2-(2',4'-dibromophenoxy)-4,6-dibromophenol from Dysidea granulosa. Mar Drugs. 2009; 7(3):464-71. PMC: 2763112. DOI: 10.3390/md7030464. View

10.

Alanis A . Resistance to antibiotics: are we in the post-antibiotic era?. Arch Med Res. 2005; 36(6):697-705. DOI: 10.1016/j.arcmed.2005.06.009. View

11.

Doern G, Pfaller M, Erwin M, Brueggemann A, Jones R . The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 1999; 32(4):313-6. DOI: 10.1016/s0732-8893(98)00081-9. View

12.

Paterson D, Ko W, von Gottberg A, Mohapatra S, Casellas J, Goossens H . International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004; 140(1):26-32. DOI: 10.7326/0003-4819-140-1-200401060-00008. View

13.

Fourati-Ben Fguira L, Fotso S, Ben Ameur-Mehdi R, Mellouli L, Laatsch H . Purification and structure elucidation of antifungal and antibacterial activities of newly isolated Streptomyces sp. strain US80. Res Microbiol. 2005; 156(3):341-7. DOI: 10.1016/j.resmic.2004.10.006. View

14.

Chang S, Sievert D, Hageman J, Boulton M, Tenover F, Downes F . Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003; 348(14):1342-7. DOI: 10.1056/NEJMoa025025. View

15.

PRIDHAM T, Gottlieb D . The Utilization of Carbon Compounds by Some Actinomycetales as an Aid for Species Determination. J Bacteriol. 1948; 56(1):107-14. PMC: 518551. DOI: 10.1128/jb.56.1.107-114.1948. View

16.

Bozdogan B, Esel D, Whitener C, Browne F, Appelbaum P . Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother. 2003; 52(5):864-8. DOI: 10.1093/jac/dkg457. View

17.

Li Y, Xu Y, Liu L, Han Z, Lai P, Guo X . Five new amicoumacins isolated from a marine-derived bacterium Bacillus subtilis. Mar Drugs. 2012; 10(2):319-328. PMC: 3296999. DOI: 10.3390/md10020319. View

18.

Yoo J, Kim J, Ha J, Park N, Sohng J, Lee J . Production and biological activity of laidlomycin, anti-MRSA/VRE antibiotic from Streptomyces sp. CS684. J Microbiol. 2007; 45(1):6-10. View

19.

Urban C, Segal-Maurer S, Rahal J . Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis. 2003; 36(10):1268-74. DOI: 10.1086/374847. View

20.

Wenzel R . The antibiotic pipeline--challenges, costs, and values. N Engl J Med. 2004; 351(6):523-6. DOI: 10.1056/NEJMp048093. View